• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    2/28/22 1:25:12 PM ET
    $AMYT
    $CINC
    $CLSN
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMYT alert in real time by email

     

    Gainers

    • IntriCon (NASDAQ:IIN) shares increased by 37.4% to $23.93 during Monday's regular session. The current volume of 1.0 million shares is 3684.0% of IntriCon's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $218.7 million. The company's, Q4 earnings came out today.
    • Reata Pharmaceuticals (NASDAQ:RETA) stock moved upwards by 22.46% to $32.0. The current volume of 1.7 million shares is 185.7% of Reata Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $1.1 billion. As per the press release, Q4 earnings came out today.
    • Cormedix (NASDAQ:CRMD) shares rose 21.89% to $4.9. As of 12:30 EST, this security is trading at a volume of 655.3K shares, making up 398.1% of its average full-day volume over the last 100 days. The company's market cap stands at $186.6 million.
    • Homology Medicines (NASDAQ:FIXX) stock rose 17.93% to $3.25. Homology Medicines's stock is trading at a volume of 840.1K shares as of 12:30 EST. This is 152.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $186.0 million.
    • Ontrak (NASDAQ:OTRKP) stock rose 15.87% to $10.29.
    • Rezolute (NASDAQ:RZLT) stock rose 13.79% to $2.73. The market value of their outstanding shares is at $42.4 million.

     

    Losers

    • CinCor Pharma (NASDAQ:CINC) stock fell 28.4% to $20.4 during Monday's regular session. As of 12:30 EST, CinCor Pharma's stock is trading at a volume of 127.9K, which is 43.2% of its average full-day volume over the last 100 days. The company's market cap stands at $744.9 million.
    • Lexicon Pharmaceuticals (NASDAQ:LXRX) shares decreased by 23.91% to $2.17. As of 12:30 EST, this security is trading at a volume of 1.6 million shares, making up 267.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $322.9 million. The company's, Q4 earnings came out today.
    • Amryt Pharma (NASDAQ:AMYT) shares fell 18.82% to $6.6. As of 12:30 EST, this security is trading at a volume of 849.1K shares, making up 650.1% of its average full-day volume over the last 100 days. The company's market cap stands at $422.1 million.
    • Celyad Oncology (NASDAQ:CYAD) stock declined by 14.6% to $2.75. The company's market cap stands at $62.1 million.
    • Prelude Therapeutics (NASDAQ:PRLD) stock declined by 13.38% to $9.0. Trading volume for Prelude Therapeutics's stock is 288.6K as of 12:30 EST. This is 78.1% of its average full-day volume over the last 100 days. The company's market cap stands at $424.9 million.
    • Celsion (NASDAQ:CLSN) stock fell 13.31% to $0.33. As of 12:30 EST, this security is trading at a volume of 1.0 million shares, making up 160.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $28.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMYT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMYT
    $CINC
    $CLSN
    $CRMD

    CompanyDatePrice TargetRatingAnalyst
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    CorMedix Inc.
    $CRMD
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    CorMedix Inc.
    $CRMD
    6/30/2025Buy → Hold
    D. Boral Capital
    CorMedix Inc.
    $CRMD
    6/30/2025$20.00Buy
    H.C. Wainwright
    CorMedix Inc.
    $CRMD
    3/7/2025$18.00Outperform
    Leerink Partners
    Lexicon Pharmaceuticals Inc.
    $LXRX
    3/5/2025$2.00 → $1.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $AMYT
    $CINC
    $CLSN
    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:18:04 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:16:14 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Elam Nevan C covered exercise/tax liability with 27,618 shares, decreasing direct ownership by 4% to 613,501 units (SEC Form 4)

    4 - Rezolute, Inc. (0001509261) (Issuer)

    3/4/26 6:07:36 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $147,000 worth of shares (100,000 units at $1.47), increasing direct ownership by 6% to 1,904,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/25/26 7:00:27 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Debbane Raymond bought $219,755 worth of shares (150,000 units at $1.47), increasing direct ownership by 9% to 1,804,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/23/26 7:49:43 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

    THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of kidney function on the long-term efficacy and safety of sotagliflozin on people with type 1 diabetes will be delivered as a short oral presentation tomorrow, March 12, during the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The congress is being held March 11-14, 2026, in Barcelona, Spain. "Recognizing that a patient's kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-des

    3/11/26 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

    Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND enabling studies for PRT13722, highly-selective oral KAT6A degrader underway, and the Company intends to file the IND for PRT13722 in mid-2026 with Phase 1 study initiation anticipated in the 2nd half of 2026 Current cash runway expected into second quarter of 2027 with $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025  WILMINGTON, Del., March

    3/10/26 7:01:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth qu

    3/5/26 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Wedbush with a new price target

    Wedbush downgraded Rezolute from Outperform to Neutral and set a new price target of $1.00

    12/11/25 10:36:07 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    SEC Filings

    View All

    SEC Form 8-K filed by Prelude Therapeutics Incorporated

    8-K - Prelude Therapeutics Inc (0001678660) (Filer)

    3/12/26 4:18:23 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Prelude Therapeutics Incorporated

    424B5 - Prelude Therapeutics Inc (0001678660) (Filer)

    3/12/26 4:16:15 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Prelude Therapeutics Incorporated

    S-8 - Prelude Therapeutics Inc (0001678660) (Filer)

    3/10/26 8:40:57 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    Leadership Updates

    Live Leadership Updates

    View All

    CorMedix Therapeutics Announces Leadership and Board Updates

    BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director. "Under t

    1/8/26 8:05:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

    WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial leadership and investment banking. "Katina brings to Prelude an abundance of experience as a strategic and financial advisor to our leadership team," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude. "We welcome her to our board and we look forward to

    10/17/25 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    11/14/24 4:34:05 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMYT
    $CINC
    $CLSN
    $CRMD
    Financials

    Live finance-specific insights

    View All

    CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth qu

    3/5/26 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

    Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  "

    3/5/26 6:59:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

    BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5th @ 8:30am ETDomestic:   1-844-676-2922International: 1-412-634-6840Webcast:   Webcast Link   About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializi

    3/2/26 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care